Stryker: Cash Flow Returns On Investments Analysis (NYSE:SYK)


Neuron Receptor and synapse activity medical concept

jitendrajadhav/iStock via Getty Images

We are initiating Stryker (NYSE:SYK) with a hold rating. This is a high-quality company with a solid history of growth, high margins, and stable returns. However, we believe the company is slightly overvalued, and better opportunities exist elsewhere.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *